Novel immune checkpoint blocker approved for the treatment of advanced melanoma

OncoImmunology

Volumn 3, Issue 11, 2014, Pages e967147-1-e967147-5

  Galluzzi, Lorenzo ^a,b,c,d   Kroemer, Guido ^a,b,c,d,e   Eggermont, Alexander ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

CTLA4; ipilimumab; Keytruda ; nivolumab; PD 1; Yervoy

Indexed keywords

CD134 ANTIGEN; DURVALUMAB; GLYCOPROTEIN GP 100; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; IPILIMUMAB; LENALIDOMIDE; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1;

EDITORIAL; HUMAN; MELANOMA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR MICROENVIRONMENT;

EID: 84921398753     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.967147     Document Type: Editorial

References (133)

1. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
2. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, W.H.Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297
3. A.Chawla, A.V.Philips, G.Alatrash, E.Mittendorf. Immune checkpoints: a therapeutic target in triple negative breast cancer. Oncoimmunology 2014; 3:e28325; PMID:24843833; http://dx.doi.org/10.4161/onci.28325
4. J.R.Brahmer. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 2014; 41:126-32; PMID:24565586; http://dx.doi.org/10.1053/j.seminoncol.2013.12.014
5. J.Weber. Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37:430-9; PMID:21074057; http://dx.doi.org/10.1053/j.seminoncol.2010.09.005
6. A.K.Nowak. Immunological checkpoint inhibitors enter adolescence. Lancet Oncol 2013; 14:1035-7; PMID:24035406; http://dx.doi.org/10.1016/S1470-2045(13)70401-7
7. F.S.Hodi, S.J.O’Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
8. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy. Nat Rev Drug Discov 2010; 9:584; PMID:20671754; http://dx.doi.org/10.1038/nrd3245
9. M.K.Erdmann. Immunity unleashed in melanoma. Lancet Oncol 2010; 11:108-9; PMID:20152761; http://dx.doi.org/10.1016/S1470-2045(09)70400-0
10. J.D.Wolchok, B.Neyns, G.Linette, S.Negrier, J.Lutzky, L.Thomas, W.Waterfield, D.Schadendorf, M.Smylie, T.GuthrieJr, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/S1470-2045(09)70334-1
11. V.K.Sondak, K.S.Smalley, R.Kudchadkar, S.Grippon, P.Kirkpatrick. Ipilimumab. Nat Rev Drug Discov 2011; 10:411-2; PMID:21629286; http://dx.doi.org/10.1038/nrd3463
12. T.L.Walunas, D.J.Lenschow, C.Y.Bakker, P.S.Linsley, G.J.Freeman, J.M.Green, C.B.Thompson, J.A.Bluestone. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13; PMID:7882171; http://dx.doi.org/10.1016/1074-7613(94)90071-X
13. E.A.Tivol, F.Borriello, A.N.Schweitzer, W.P.Lynch, J.A.Bluestone, A.H.Sharpe. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541-7; PMID:7584144; http://dx.doi.org/10.1016/1074-7613(95)90125-6
14. P.Waterhouse, J.M.Penninger, E.Timms, A.Wakeham, A.Shahinian, K.P.Lee, C.B.Thompson, H.Griesser, T.W.Mak. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270:985-8; PMID:7481803; http://dx.doi.org/10.1126/science.270.5238.985
15. L.Robert, C.Harview, R.Emerson, X.Wang, S.Mok, B.Homet, B.Comin-Anduix, R.C.Koya, H.Robins, P.C.Tumeh, Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology 2014; 3:e29244; PMID:25083336; http://dx.doi.org/10.4161/onci.29244
16. L.C.Sandin, F.Eriksson, P.Ellmark, A.S.Loskog, T.H.Totterman, S.M.Mangsbo. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology 2014; 3:e27614; PMID:24701377; http://dx.doi.org/10.4161/onci.27614
17. C.Robert, A.Ribas, J.D.Wolchok, F.S.Hodi, O.Hamid, R.Kefford, J.S.Weber, A.M.Joshua, W.J.Hwu, T.C.Gangadhar, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17; PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2
18. A.Ribas, F.S.Hodi, R.Kefford, O.Hamid, A.Daud, J.D.Wolchok, Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). ASCO Meeting Abstr 2014; 32:LBA9000.
19. E.D.Deeks. Nivolumab: a review of its use in patients with malignant melanoma. Drugs 2014; 74:1233-9; PMID:25022950; http://dx.doi.org/10.1007/s40265-014-0234-4
20. Improved survival ends nivolumab trial early. Cancer Discov 2014; 4:979-80; PMID:25185170; http://dx.doi.org/10.1158/2159-8290.CD-NB2014-104
21. S.L.Topalian, M.Sznol, D.F.McDermott, H.M.Kluger, R.D.Carvajal, W.H.Sharfman, J.R.Brahmer, D.P.Lawrence, M.B.Atkins, J.D.Powderly, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
22. J.S.Weber, R.R.Kudchadkar, B.Yu, D.Gallenstein, C.E.Horak, H.D.Inzunza, X.Zhao, A.J.Martinez, W.Wang, G.Gibney, Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013; 31:4311-8; PMID:24145345; http://dx.doi.org/10.1200/JCO.2013.51.4802
23. J.D.Wolchok, H.Kluger, M.K.Callahan, M.A.Postow, N.A.Rizvi, A.M.Lesokhin, N.H.Segal, C.E.Ariyan, R.A.Gordon, K.Reed, Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
24. E.J.Lipson. Re-orienting the immune system: durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. Oncoimmunology 2013; 2:e23661; PMID:23734322; http://dx.doi.org/10.4161/onci.23661
25. K.A.Schalper. PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer. Oncoimmunology 2014; 3:e29288; PMID:25083339; http://dx.doi.org/10.4161/onci.29288
26. S.Munir, G.H.Andersen, I.M.Svane, M.H.Andersen. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells. Oncoimmunology 2013; 2:e23991; PMID:23734334; http://dx.doi.org/10.4161/onci.23991
27. J.R.Brahmer, S.S.Tykodi, L.Q.Chow, W.J.Hwu, S.L.Topalian, P.Hwu, C.G.Drake, L.H.Camacho, J.Kauh, K.Odunsi, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
28. E.Vacchelli, A.Eggermont, J.Galon, C.Sautes-Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/10.4161/onci.22789
29. J.Lu, L.Lee-Gabel, M.C.Nadeau, T.M.Ferencz, S.A.Soefje. Clinical evaluation of compounds targeting PD-1PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract 2014; PMID:24917416
30. B.C.Creelan. Update on immune checkpoint inhibitors in lung cancer. Cancer Control 2014; 21:80-9; PMID:24357746
31. P.A.Ascierto, M.Kalos, D.A.Schaer, M.K.Callahan, J.D.Wolchok. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013; 19:1009-20; PMID:23460532; http://dx.doi.org/10.1158/1078-0432.CCR-12-2982
32. J.R.Brahmer, N.A.Rizvi, J.Lutzky, S.Khleif, A.Blake-Haskins, X.Li, Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. ASCO Meeting Abstr 2014; 32:8021.
33. M.K.Callahan, P.A.Ott, K.Odunsi, S.V.Bertolini, L.S.Pan, R.R.Venhaus, A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. ASCO Meeting Abstr 2014; 32:TPS3120.
34. J.Lutzky, S.J.Antonia, A.Blake-Haskins, X.Li, P.B.Robbins, A.M.Shalabi, A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. ASCO Meeting Abstr 2014; 32:3001.
35. N.H.Segal, S.J.Antonia, J.R.Brahmer, M.Maio, A.Blake-Haskins, X.Li, Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. ASCO Meeting Abstr 2014; 32:3002.
36. A.M.Eggermont, A.Spatz, C.Robert. Cutaneous melanoma. Lancet 2014; 383:816-27; PMID:24054424; http://dx.doi.org/10.1016/S0140-6736(13)60802-8
37. G.Dranoff. Intensifying tumour immunity through combination therapy. Lancet Oncol 2012; 13:440-2; PMID:22326921; http://dx.doi.org/10.1016/S1470-2045(12)70051-7
38. D.Mavilio, E.Lugli. Inhibiting the inhibitors: checkpoints blockade in solid tumors. Oncoimmunology 2013; 2:e26535; PMID:24244910; http://dx.doi.org/10.4161/onci.26535
39. J.L.Riley. Combination checkpoint blockade–taking melanoma immunotherapy to the next level. N Engl J Med 2013; 369:187-9; PMID:23724866; http://dx.doi.org/10.1056/NEJMe1305484
40. S.Bhatia, J.A.Thompson. Melanoma: immune checkpoint blockade story gets better. Lancet 2014; 384:1078-9; PMID:25034863; http://dx.doi.org/10.1016/S0140-6736(14)61140-5
41. K.Margolin. Treatment of advanced melanoma with immunological checkpoint block. Curr Oncol Rep 2011; 13:430-2; PMID:21938386; http://dx.doi.org/10.1007/s11912-011-0195-7
42. A.M.Eggermont, C.Robert. Melanoma: smart therapeutic strategies in immuno-oncology. Nat Rev Clin Oncol 2014; 11:181-2; PMID:24590131; http://dx.doi.org/10.1038/nrclinonc.2014.36
43. R.S.Andersen, S.R.Andersen, M.D.Hjortso, R.Lyngaa, M.Idorn, T.M.Kollgard, O.Met, P.Thor Straten, S.R.Hadrup. High frequency of T cells specific for cryptic epitopes in melanoma patients. Oncoimmunology 2013; 2:e25374; PMID:24073381; http://dx.doi.org/10.4161/onci.25374
44. G.Bindea, B.Mlecnik, H.K.Angell, J.Galon. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology 2014; 3:e27456; PMID:24800163; http://dx.doi.org/10.4161/onci.27456
45. A.Eggermont, C.Robert, J.C.Soria, L.Zitvogel. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. Oncoimmunology 2014; 3:e27560; PMID:24719793; http://dx.doi.org/10.4161/onci.27560
46. M.K.Callahan, J.C.Bendell, E.Chan, M.Morse, R.N.Pillai, P.Bono, Phase III, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors. ASCO Meeting Abstr 2014; 32:TPS3114.
47. C.R.Heery, G.H.O’Sullivan Coyne, R.A.Madan, J.Schlom, A.von Heydebreck, J.-M.Cuillerot, Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. ASCO Meeting Abstr 2014; 32:3064.
48. G.Garcia-Manero, G.Martinelli, J.F.Zeidner, D.Avigan, K.C.Anderson, V.Ribrag, A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies. ASCO Meeting Abstr 2014; 32:TPS3116.
49. S.Ansen, A.M.Schultheis, M.Hellmich, T.Zander, M.Brockmann, E.Stoelben, PD-L1 expression and genotype in non-small cell lung cancer (NSCLC). ASCO Meeting Abstr 2014; 32:7517.
50. J.R.Brahmer, L.Horn, S.J.Antonia, D.R.Spigel, L.Gandhi, L.V.Sequist, Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstr 2013; 31:8030.
51. J.R.Brahmer, L.Horn, L.Gandhi, D.R.Spigel, S.J.Antonia, N.A.Rizvi, Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. ASCO Meeting Abstr 2014; 32:8112.
52. A.Calles, X.Liao, L.M.Sholl, M.Butaney, S.J.Rodig, G.J.Freeman, Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant non-small cell lung cancer in never-smokers. ASCO Meeting Abstr 2014; 32:8032.
53. D.P.Carbone, M.A.Socinski, A.C.Chen, P.Bhagavatheeswaran, M.Reck, L.Paz-Ares. A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC). ASCO Meeting Abstr 2014; 32:TPS8128.
54. E.B.Garon, N.B.Leighl, N.A.Rizvi, G.R.Blumenschein, A.S.Balmanoukian, J.P.Eder, Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). ASCO Meeting Abstr 2014; 32:8020.
55. D.R.Spigel, S.N.Gettinger, L.Horn, R.S.Herbst, L.Gandhi, M.S.Gordon, Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstr 2013; 31:8008.
56. M.Callea, E.M.Genega, M.Gupta, S.Cheng, A.P.Fay, J.Song, PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. ASCO Meeting Abstr 2014; 32:4585.
57. M.Callea, E.M.Genega, M.Gupta, A.P.Fay, J.Song, I.Carvo, PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. ASCO Meeting Abstr 2014; 32:467.
58. T.K.Choueiri, M.N.Fishman, B.J.Escudier, J.J.Kim, H.M.Kluger, W.M.Stadler, Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial. ASCO Meeting Abstr 2014; 32:5012.
59. C.G.Drake, D.F.McDermott, M.Sznol, T.K.Choueiri, H.M.Kluger, J.D.Powderly, Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up. ASCO Meeting Abstr 2013; 31:4514.
60. A.P.Fay, M.Callea, K.P.Gray, T.H.Ho, J.Song, I.Carvo, PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors. ASCO Meeting Abstr 2014; 32:4526.
61. S.P.D’Angelo, A.N.Shoushtari, N.P.Agaram, D.Kuk, L.-X.Qin, R.D.Carvajal, PD-L1 expression and immune infiltrates in sarcoma. ASCO Meeting Abstr 2014; 32:10522.
62. N.Junker, M.Donia, R.Andersen, M.H.Andersen, I.M.Svane. PD-L1 specific tumor infiltrating lymphocytes occur frequently in melanoma and HNSCC patients. ASCO Meeting Abstr 2014; 32:11083.
63. T.Y.Seiwert, B.Burtness, J.Weiss, I.Gluck, J.P.Eder, S.I.Pai, A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (HN) cancer. ASCO Meeting Abstr 2014; 32:6011.
64. J.Hamanishi, M.Mandai, T.Ikeda, M.Minami, A.Kawaguchi, N.Matsumura, Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. ASCO Meeting Abstr 2014; 32:5511.
65. T.Powles, N.J.Vogelzang, G.D.Fine, J.P.Eder, F.S.Braiteh, Y.Loriot, Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). ASCO Meeting Abstr 2014; 32:5011.
66. S.K.Padda, J.Riess, E.J.Schwartz, L.Tian, H.E.Kohrt, J.W.Neal, Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA). ASCO Meeting Abstr 2014; 32:7606.
67. N.J.Llosa, F.Housseau, E.C.Wick, L.Hechenbleikner, M.Cruise, R.Anders, Immune checkpoints expression in MSI versus MSS colorectal cancers and their potential therapeutic implications. ASCO Meeting Abstr 2014; 32:3620.
68. E.Vacchelli, F.Aranda, F.Obrist, A.Eggermont, J.Galon, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; http://dx.doi.org/10.4161/onci.29030
69. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; http://dx.doi.org/10.4161/onci.24850
70. A.J.van den Eertwegh, J.Versluis, H.P.van den Berg, S.J.Santegoets, R.J.van Moorselaar, T.M.van der Sluis, H.E.Gall, T.C.Harding, K.Jooss, I.Lowy, Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509-17; PMID:22326922; http://dx.doi.org/10.1016/S1470-2045(12)70007-4
71. S.N.Linch, W.L.Redmond. Combined OX40 ligation plus CTLA-4 blockade: more than the sum of its parts. Oncoimmunology 2014; 3:e28245; PMID:25050194; http://dx.doi.org/10.4161/onci.28245
72. L.B.John, M.H.Kershaw, P.K.Darcy. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2013; 2:e26286; PMID:24353912; http://dx.doi.org/10.4161/onci.26286
73. L.B.John, C.Devaud, C.P.Duong, C.S.Yong, P.A.Beavis, N.M.Haynes, M.T.Chow, M.J.Smyth, M.H.Kershaw, P.K.Darcy. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013; 19:5636-46; PMID:23873688; http://dx.doi.org/10.1158/1078-0432.CCR-13-0458
74. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/10.4161/onci.24238
75. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, W.Herve Fridman, I.Cremer, E.Tartour, L.Zitvogel, G.Kroemer, Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2014; 3:e28344; PMID:25050207; http://dx.doi.org/10.4161/onci.28344
76. W.Peng, G.Lizee, P.Hwu. Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. Oncoimmunology 2013; 2:e22691; PMID:23524510; http://dx.doi.org/10.4161/onci.22691
77. W.Peng, C.Liu, C.Xu, Y.Lou, J.Chen, Y.Yang, H.Yagita, W.W.Overwijk, G.Lizée, L.Radvanyi, PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012; 72:5209-18; PMID:22915761; http://dx.doi.org/10.1158/0008-5472.CAN-12-1187
78. E.Vacchelli, I.Vitale, A.Eggermont, W.H.Fridman, J.Fucikova, I.Cremer, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; PMID:24286020; http://dx.doi.org/10.4161/onci.25771
79. N.Bloy, J.Pol, F.Aranda, A.Eggermont, I.Cremer, W.H.Fridman, J.Galon, C.Sautès-Fridman, E.Tartour, L.Zitvogel, Trial Watch: dendritic cell-based anticancer therapy. Oncoimmunology 2014; 3:in press.
80. R.A.Madan, M.Mohebtash, P.M.Arlen, M.Vergati, M.Rauckhorst, S.M.Steinberg, K.Y.Tsang, D.J.Poole, H.L.Parnes, J.J.Wright, Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:501-8; PMID:22326924; http://dx.doi.org/10.1016/S1470-2045(12)70006-2
81. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
82. L.Senovilla, E.Vacchelli, P.Garcia, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013; 2:e23803; PMID:23734328; http://dx.doi.org/10.4161/onci.23803
83. J.Pol, N.Bloy, F.Obrist, A.Eggermont, J.Galon, Herve W.Fridman, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2014; 3:e28185; PMID:24800178; http://dx.doi.org/10.4161/onci.28185
84. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621
85. J.Rosenblatt, B.Glotzbecker, H.Mills, B.Vasir, D.Tzachanis, J.D.Levine, R.M.Joyce, K.Wellenstein, W.Keefe, M.Schickler, PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cellmyeloma fusion vaccine. J Immunother 2011; 34:409-18; PMID:21577144; http://dx.doi.org/10.1097/CJI.0b013e31821ca6ce
86. J.S.Weber, R.R.Kudchadkar, G.T.Gibney, B.Yu, P.Cheng, A.J.Martinez, Updated survival, toxicity, and biomarkers of nivolumab withwithout peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI). ASCO Meeting Abstr 2014; 32:3009.
87. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, C.Sautes-Fridman, I.Cremer, J.Henrik Ter Meulen, L.Zitvogel, G.Kroemer, Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3:e29179; PMID:25083332; http://dx.doi.org/10.4161/onci.29179
88. E.Vacchelli, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http://dx.doi.org/10.4161/onci.25238
89. T.Nagato, E.Celis. A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1PD-L1 pathway. Oncoimmunology 2014; 3:e28440; PMID:25050210; http://dx.doi.org/10.4161/onci.28440
90. C.A.Barker, M.A.Postow, S.A.Khan, K.Beal, P.K.Parhar, Y.Yamada, N.Y.Lee, J.D.Wolchok. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013; 1:92-8; PMID:24777500; http://dx.doi.org/10.1158/2326-6066.CIR-13-0082
91. N.Bloy, J.Pol, G.Manic, I.Vitale, A.Eggermont, J.Galon, Trial watch: radioimmunotherapy for oncological indications. Oncoimmunology 2014; 3:in press.
92. E.Vacchelli, I.Vitale, E.Tartour, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634
93. A.W.Silk, M.F.Bassetti, B.T.West, C.I.Tsien, C.D.Lao. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2:899-906; PMID:24403263; http://dx.doi.org/10.1002/cam4.140
94. S.M.Hiniker, D.S.Chen, S.J.Knox. Abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:2035; author reply -6; PMID:22621637; http://dx.doi.org/10.1056/NEJMc1203984
95. M.A.Postow, M.K.Callahan, C.A.Barker, Y.Yamada, J.Yuan, S.Kitano, Z.Mu, T.Rasalan, M.Adamow, E.Ritter, Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824
96. S.Demaria, K.A.Pilones, S.C.Formenti, M.L.Dustin. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology 2013; 2:e23127; PMID:23802063; http://dx.doi.org/10.4161/onci.23127
97. E.Vacchelli, L.Senovilla, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; http://dx.doi.org/10.4161/onci.23510
98. E.Vacchelli, F.Aranda, A.Eggermont, J.Galon, C.Sautes-Fridman, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014; 3:e27878; PMID:24800173; http://dx.doi.org/10.4161/onci.27878
99. L.Galluzzi, L.Senovilla, L.Zitvogel, G.Kroemer. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
100. L.Zitvogel, L.Galluzzi, M.J.Smyth, G.Kroemer. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
101. Z.A.Cooper, D.T.Frederick, Z.Ahmed, J.A.Wargo. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology 2013; 2:e24320; PMID:23762807; http://dx.doi.org/10.4161/onci.24320
102. A.Amin, M.S.Ernstoff, J.R.Infante, Heng DYC, B.I.Rini, E.R.Plimack, A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstr 2013; 31:TPS4593.
103. A.Amin, E.R.Plimack, J.R.Infante, M.S.Ernstoff, B.I.Rini, D.F.McDermott, Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstr 2014; 32:5010.
104. S.J.Antonia, J.R.Brahmer, S.N.Gettinger, L.Q.M.Chow, R.A.Juergens, F.A.Shepherd, Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstr 2014; 32:8113.
105. K.Flaherty, A.Daud, J.S.Weber, J.A.Sosman, K.Kim, R.Gonzalez, Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). ASCO Meeting Abstr 2014; 32:9010.
106. D.F.McDermott, J.R.Infante, M.H.Voss, R.J.Motzer, J.B.A.G.Haanen, S.Chowdhury, A phase III study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma. ASCO Meeting Abstr 2014; 32:TPS4604.
107. K.Porkka, M.J.Mauro, J.H.Lipton, F.-X.Mahon, L.C.Strauss, W.J.Geese, An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML). ASCO Meeting Abstr 2014; 32:TPS7119.
108. N.A.Rizvi, L.Q.M.Chow, H.Borghaei, Y.Shen, C.Harbison, S.Alaparthy, Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. ASCO Meeting Abstr 2014; 32:8022.
109. A.Melcher, K.Parato, C.M.Rooney, J.C.Bell. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011; 19:1008-16; PMID:21505424; http://dx.doi.org/10.1038/mt.2011.65
110. J.Pol, N.Bloy, F.Obrist, A.Eggermont, J.Galon, I.Cremer, P.Erbs, J.M.Limacher, X.Preville, L.Zitvogel, Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3:e28694; PMID:25097804; http://dx.doi.org/10.4161/onci.28694
111. E.Vacchelli, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2013; 2:e24612; PMID:23894720; http://dx.doi.org/10.4161/onci.24612
112. D.Zamarin, R.B.Holmgaard, S.K.Subudhi, J.S.Park, M.Mansour, P.Palese, T.Merghoub, J.D.Wolchok, J.P.Allison. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014; 6:226ra32; PMID:24598590; http://dx.doi.org/10.1126/scitranslmed.3008095
113. F.S.Hodi, D.Lawrence, C.Lezcano, X.Wu, J.Zhou, T.Sasada, W.Zeng, A.Giobbie-Hurder, M.B.Atkins, N.Ibrahim, Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2:632-42; PMID:24838938; http://dx.doi.org/10.1158/2326-6066.CIR-14-0053
114. E.Vacchelli, F.Aranda, A.Eggermont, J.Galon, C.Sautes-Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:24605265; http://dx.doi.org/10.4161/onci.27048
115. D.S.D.Siegel, P.Moreau, D.Avigan, K.C.Anderson, D.E.Reece, J.San Miguel, A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsedrefractory multiple myeloma (RRMM). ASCO Meeting Abstr 2014; 32:TPS3117.
116. M.Semeraro, E.Vacchelli, A.Eggermont, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: lenalidomide-based immunochemotherapy. Oncoimmunology 2013; 2:e26494; PMID:24482747; http://dx.doi.org/10.4161/onci.26494
117. M.Semeraro, L.Galluzzi. Novel insights into the mechanism of action of lenalidomide. Oncoimmunology 2014; 3:e28386; PMID:25340011; http://dx.doi.org/10.4161/onci.28386
118. H.J.Hammers, E.R.Plimack, J.R.Infante, M.S.Ernstoff, B.I.Rini, D.F.McDermott, Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstr 2014; 32:4504.
119. R.E.Sanborn, W.H.Sharfman, N.H.Segal, F.S.Hodi, J.D.Wolchok, W.J.Urba, A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors. ASCO Meeting Abstr 2013; 31:TPS3110.
120. N.H.Segal, F.S.Hodi, R.E.Sanborn, T.Gajewski, J.D.Wolchok, W.J.Urba, A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors. ASCO Meeting Abstr 2014; 32:TPS3115.
121. E.Vacchelli, N.Prada, O.Kepp, L.Galluzzi. Current trends of anticancer immunochemotherapy. Oncoimmunology 2013; 2:e25396; PMID:23894726; http://dx.doi.org/10.4161/onci.25396
122. J.M.Taube, A.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim, L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
123. H.Kakavand, R.A.Scolyer, J.F.Thompson, G.J.Mann. Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. Oncoimmunology 2013; 2:e25564; PMID:24228228; http://dx.doi.org/10.4161/onci.25564
124. M.Rodolfo, C.Castelli, L.Rivoltini. Immune response markers in sentinel nodes may predict melanoma progression. Oncoimmunology 2014; 3:e28498; PMID:25050216; http://dx.doi.org/10.4161/onci.28498
125. M.A.Morse, T.Osada, A.Hobeika, S.Patel, H.K.Lyerly. Biomarkers and correlative endpoints for immunotherapy trials. Am Soc Clin Oncol Educ Book 2013; PMID:23714525; http://dx.doi.org/10.1200/EdBook_AM.2013.33.e287
126. I.Melero, G.Gaudernack, W.Gerritsen, C.Huber, G.Parmiani, S.Scholl, N.Thatcher, J.Wagstaff, C.Zielinski, I.Faulkner, Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 2014; 11:509-24; PMID:25001465; http://dx.doi.org/10.1038/nrclinonc.2014.111
127. L.Senovilla, E.Vacchelli, J.Galon, S.Adjemian, A.Eggermont, W.H.Fridman, C.Sautès-Fridman, Y.Ma, E.Tartour, L.Zitvogel, Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/onci.22009
128. A.F.Lee, P.A.Sieling, D.J.Lee. Immune correlates of melanoma survival in adoptive cell therapy. Oncoimmunology 2013; 2:e22889; PMID:23525606; http://dx.doi.org/10.4161/onci.22889
129. F.S.Hodi, A.Ribas, A.Daud, O.Hamid, C.Robert, R.Kefford, Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meeting Abstr 2014; 32:3006.
130. J.Delyon, C.Mateus, T.Lambert. Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365:1747-8; PMID:22047582; http://dx.doi.org/10.1056/NEJMc1110923
131. F.Fadel, El K.Karoui, B.Knebelmann. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361:211-2; PMID:19587352; http://dx.doi.org/10.1056/NEJMc0904283
132. A.Ribas, F.S.Hodi, M.Callahan, C.Konto, J.Wolchok. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6; PMID:23550685; http://dx.doi.org/10.1056/NEJMc1302338
133. B.A.Baldo. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology 2013; 2:e26333; PMID:24251081; http://dx.doi.org/10.4161/onci.26333